Precision Medicine And Immune Sequencing Will Expand Diagnostic Horizons
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
06 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$15.00
13.1% undervalued intrinsic discount16 Aug
US$13.04
1Y
170.0%7D
6.9%